sch-58500
Gene therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 1999 (NCT00003880)
Timeline
Indications
Mechanism of action
- Cellular tumor antigen p53Supplementation
TP53 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- sch-58500
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00004080 | Phase 1 | Dec 1, 1999 | Emory University, National Cancer Institute (NCI) |
| NCT00002960 | Phase 1 | Jun 1, 1999 | Merck, Schering-Plough |
| NCT00003880 | Phase 2/Phase 3 (Phase 3) | Feb 1, 1999 | Merck, Schering-Plough |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 2 | 2 | 2 | 1999 |
| Schering-Plough | For profit | 2 | 0 | 2 | 1999 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 1999 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 1999 |
4 organizations
Page 1 / 1